25 XP   0   0   10

Oramed Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Oramed together

PenkeI guess you are interested in Oramed Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Oramed Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Oramed Pharmaceuticals Inc

I send you an email if I find something interesting about Oramed Pharmaceuticals Inc.

Quick analysis of Oramed (30 sec.)










What can you expect buying and holding a share of Oramed? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$4.02
Expected worth in 1 year
$4.31
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$0.29
Return On Investment
13.2%

For what price can you sell your share?

Current Price per Share
$2.20
Expected price per share
$2.1 - $3.62
How sure are you?
50%

1. Valuation of Oramed (5 min.)




Live pricePrice per Share (EOD)

$2.20

Intrinsic Value Per Share

$-4.17 - $4.44

Total Value Per Share

$-0.15 - $8.46

2. Growth of Oramed (5 min.)




Is Oramed growing?

Current yearPrevious yearGrowGrow %
How rich?$162.8m$154.8m-$1.6m-1.1%

How much money is Oramed making?

Current yearPrevious yearGrowGrow %
Making money$94.2k-$9.1m$9.2m9,849.1%
Net Profit Margin-357.9%-1,361.5%--

How much money comes from the company's main activities?

3. Financial Health of Oramed (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#285 / 1016

Most Revenue
#573 / 1016

Most Profit
#169 / 1016

Most Efficient
#708 / 1016

What can you expect buying and holding a share of Oramed? (5 min.)

Welcome investor! Oramed's management wants to use your money to grow the business. In return you get a share of Oramed.

What can you expect buying and holding a share of Oramed?

First you should know what it really means to hold a share of Oramed. And how you can make/lose money.

Speculation

The Price per Share of Oramed is $2.2. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Oramed.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Oramed, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.02. Based on the TTM, the Book Value Change Per Share is $0.07 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.12 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Oramed.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.3315.0%0.052.2%-0.23-10.3%-0.10-4.5%-0.07-3.3%
Usd Book Value Change Per Share0.3616.4%0.073.3%-0.12-5.5%0.177.5%0.104.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.3616.4%0.073.3%-0.12-5.5%0.177.5%0.104.4%
Usd Price Per Share2.22-2.91-7.99-6.59-7.06-
Price to Earnings Ratio1.69--15.18--9.19--11.34--18.52-
Price-to-Total Gains Ratio6.13--125.14-727.86-110.40--8.15-
Price to Book Ratio0.55-0.77-2.08-4.47-8.93-
Price-to-Total Gains Ratio6.13--125.14-727.86-110.40--8.15-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.2
Number of shares454
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.070.17
Usd Total Gains Per Share0.070.17
Gains per Quarter (454 shares)32.8875.09
Gains per Year (454 shares)131.51300.36
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101321220300290
202632540601590
303953860901890
40526518012011190
50658650015021490
60789782018021790
70921914021032090
8010521046024032390
9011841178027032690
10013151310030042990

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%3.017.00.015.0%6.034.00.015.0%7.067.00.09.5%
Book Value Change Per Share1.02.01.025.0%6.05.01.050.0%7.012.01.035.0%13.026.01.032.5%22.048.04.029.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.074.00.0%
Total Gains per Share1.02.01.025.0%6.05.01.050.0%7.012.01.035.0%13.026.01.032.5%22.048.04.029.7%

Fundamentals of Oramed

About Oramed Pharmaceuticals Inc

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Fundamental data was last updated by Penke on 2024-04-11 17:08:07.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Oramed Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Oramed earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Oramed to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Oramed Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-357.9%+357.9%
TTM-357.9%YOY-1,361.5%+1,003.6%
TTM-357.9%5Y-726.2%+368.2%
5Y-726.2%10Y-593.8%-132.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--197.2%+197.2%
TTM-357.9%-210.4%-147.5%
YOY-1,361.5%-279.3%-1,082.2%
5Y-726.2%-436.8%-289.4%
10Y-593.8%-599.3%+5.5%
1.1.2. Return on Assets

Shows how efficient Oramed is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Oramed to the Biotechnology industry mean.
  • 6.0% Return on Assets means that Oramed generated $0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Oramed Pharmaceuticals Inc:

  • The MRQ is 6.0%. Using its assets, the company is efficient in making profit. +1
  • The TTM is -0.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ6.0%TTM-0.3%+6.4%
TTM-0.3%YOY-5.6%+5.2%
TTM-0.3%5Y-6.0%+5.6%
5Y-6.0%10Y-6.7%+0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.0%-13.6%+19.6%
TTM-0.3%-12.9%+12.6%
YOY-5.6%-11.9%+6.3%
5Y-6.0%-14.2%+8.2%
10Y-6.7%-16.2%+9.5%
1.1.3. Return on Equity

Shows how efficient Oramed is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Oramed to the Biotechnology industry mean.
  • 8.1% Return on Equity means Oramed generated $0.08 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Oramed Pharmaceuticals Inc:

  • The MRQ is 8.1%. Using its investors money, the company is less efficient in making profit.
  • The TTM is -0.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ8.1%TTM-0.1%+8.2%
TTM-0.1%YOY-5.9%+5.8%
TTM-0.1%5Y-8.5%+8.4%
5Y-8.5%10Y-9.7%+1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.1%-17.0%+25.1%
TTM-0.1%-16.1%+16.0%
YOY-5.9%-15.4%+9.5%
5Y-8.5%-20.0%+11.5%
10Y-9.7%-21.1%+11.4%

1.2. Operating Efficiency of Oramed Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Oramed is operating .

  • Measures how much profit Oramed makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Oramed to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Oramed Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-498.2%+498.2%
TTM-498.2%YOY-1,503.6%+1,005.4%
TTM-498.2%5Y-793.7%+295.6%
5Y-793.7%10Y-624.7%-169.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM-498.2%-224.4%-273.8%
YOY-1,503.6%-288.4%-1,215.2%
5Y-793.7%-475.2%-318.5%
10Y-624.7%-624.7%0.0%
1.2.2. Operating Ratio

Measures how efficient Oramed is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Oramed Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM5.482-5.482
TTM5.482YOY16.036-10.554
TTM5.4825Y8.901-3.419
5Y8.90110Y8.624+0.277
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.997-2.997
TTM5.4823.247+2.235
YOY16.0363.766+12.270
5Y8.9015.675+3.226
10Y8.6247.857+0.767

1.3. Liquidity of Oramed Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Oramed is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.06 means the company has $3.06 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Oramed Pharmaceuticals Inc:

  • The MRQ is 3.055. The company is very able to pay all its short-term debts. +2
  • The TTM is 43.534. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.055TTM43.534-40.479
TTM43.534YOY23.901+19.633
TTM43.5345Y19.043+24.491
5Y19.04310Y17.540+1.504
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0553.930-0.875
TTM43.5344.251+39.283
YOY23.9015.436+18.465
5Y19.0436.045+12.998
10Y17.5406.363+11.177
1.3.2. Quick Ratio

Measures if Oramed is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Oramed to the Biotechnology industry mean.
  • A Quick Ratio of 2.88 means the company can pay off $2.88 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Oramed Pharmaceuticals Inc:

  • The MRQ is 2.875. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 82.410. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.875TTM82.410-79.535
TTM82.410YOY35.328+47.082
TTM82.4105Y32.228+50.181
5Y32.22810Y30.814+1.414
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8753.629-0.754
TTM82.4104.065+78.345
YOY35.3285.397+29.931
5Y32.2285.993+26.235
10Y30.8146.277+24.537

1.4. Solvency of Oramed Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Oramed assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Oramed to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.26 means that Oramed assets are financed with 26.1% credit (debt) and the remaining percentage (100% - 26.1%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Oramed Pharmaceuticals Inc:

  • The MRQ is 0.261. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.180. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.261TTM0.180+0.081
TTM0.180YOY0.062+0.118
TTM0.1805Y0.223-0.043
5Y0.22310Y0.238-0.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2610.332-0.071
TTM0.1800.334-0.154
YOY0.0620.268-0.206
5Y0.2230.366-0.143
10Y0.2380.390-0.152
1.4.2. Debt to Equity Ratio

Measures if Oramed is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Oramed to the Biotechnology industry mean.
  • A Debt to Equity ratio of 35.2% means that company has $0.35 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Oramed Pharmaceuticals Inc:

  • The MRQ is 0.352. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.253. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.352TTM0.253+0.099
TTM0.253YOY0.066+0.187
TTM0.2535Y0.343-0.090
5Y0.34310Y0.396-0.052
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3520.381-0.029
TTM0.2530.390-0.137
YOY0.0660.334-0.268
5Y0.3430.434-0.091
10Y0.3960.466-0.070

2. Market Valuation of Oramed Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Oramed generates.

  • Above 15 is considered overpriced but always compare Oramed to the Biotechnology industry mean.
  • A PE ratio of 1.69 means the investor is paying $1.69 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Oramed Pharmaceuticals Inc:

  • The EOD is 1.671. Based on the earnings, the company is cheap. +2
  • The MRQ is 1.686. Based on the earnings, the company is cheap. +2
  • The TTM is -15.179. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD1.671MRQ1.686-0.015
MRQ1.686TTM-15.179+16.866
TTM-15.179YOY-9.191-5.989
TTM-15.1795Y-11.338-3.841
5Y-11.33810Y-18.521+7.183
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.671-2.315+3.986
MRQ1.686-2.560+4.246
TTM-15.179-2.664-12.515
YOY-9.191-4.122-5.069
5Y-11.338-6.258-5.080
10Y-18.521-6.108-12.413
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Oramed Pharmaceuticals Inc:

  • The EOD is -15.683. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -15.826. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -19.888. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-15.683MRQ-15.826+0.143
MRQ-15.826TTM-19.888+4.063
TTM-19.888YOY-15.956-3.932
TTM-19.8885Y-17.212-2.676
5Y-17.21210Y-26.216+9.004
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-15.683-3.067-12.616
MRQ-15.826-3.251-12.575
TTM-19.888-3.545-16.343
YOY-15.956-5.595-10.361
5Y-17.212-8.315-8.897
10Y-26.216-8.708-17.508
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Oramed is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.55 means the investor is paying $0.55 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Oramed Pharmaceuticals Inc:

  • The EOD is 0.547. Based on the equity, the company is cheap. +2
  • The MRQ is 0.552. Based on the equity, the company is cheap. +2
  • The TTM is 0.775. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.547MRQ0.552-0.005
MRQ0.552TTM0.775-0.222
TTM0.775YOY2.082-1.308
TTM0.7755Y4.470-3.696
5Y4.47010Y8.928-4.458
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.5471.905-1.358
MRQ0.5522.111-1.559
TTM0.7752.095-1.320
YOY2.0822.836-0.754
5Y4.4703.443+1.027
10Y8.9283.794+5.134
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Oramed Pharmaceuticals Inc.

3.1. Institutions holding Oramed Pharmaceuticals Inc

Institutions are holding 13.906% of the shares of Oramed Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31BML Capital Management LLC3.12742.2073126155948026761.4709
2023-12-31Murchinson Ltd.2.60290.4225105000010500000
2023-12-31BOOTHBAY FUND MANAGEMENT, LLC1.30150.0315250015250010
2023-12-31Renaissance Technologies Corp0.84550.0012341073296773669.9165
2023-12-31Rathbone Brothers PLC0.71840.004328980300
2023-12-31Two Sigma Advisers, LLC0.7030.001528360011800071.256
2023-12-31Bank of America Corp0.67280.00012714032508661221.5319
2023-12-31Two Sigma Investments LLC0.390.0008157330125805399.0642
2023-12-31Squarepoint Ops LLC0.29070.000511727664432121.9287
2023-12-31JANE STREET GROUP, LLC0.23680.00019551884606775.3482
2023-12-31BlackRock Inc0.2176087758-1040-1.1712
2023-12-31Qube Research & Technologies0.21450.00048652076630774.8231
2023-12-31Morgan Stanley - Brokerage Accounts0.159306424237286.1606
2023-12-31State Street Corporation0.143705797411602.0418
2023-12-31Susquehanna International Group, LLP0.113804591632848251.3621
2023-12-31LPL Financial Corp0.1070.000143166595015.9877
2023-12-31JPMorgan Chase & Co0.0713028766-17250-37.487
2023-12-31PNC Financial Services Group Inc0.06490.000126200-975-3.5879
2023-12-31Geode Capital Management, LLC0.0631025455454621.7418
2023-12-31American Century Companies Inc0.04780192905262.8032
Total 12.0922.66994877850+3101873+63.6%

3.2. Funds holding Oramed Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29iShares Micro-Cap ETF0.20750.03028369800
2024-02-29SPDR® Portfolio Developed Wld ex-US ETF0.11280.00084551200
2023-12-31MTF TR TA-Growth0.07921.720231945312510.8432
2023-12-31I.B.I 70/300.07810.04363148700
2024-01-31Fidelity Nasdaq Composite Index0.06310.00052545500
2023-12-31Harel Growth Equity0.04460.91871800000
2024-02-29Avantis US Small Cap Equity ETF0.03750.00661513800
2024-02-29SPDR® S&P International Small Cap ETF0.03050.00651229200
2024-02-29AJO Vista US Micro Cap Equity0.02080.256839000
2023-12-31Psagot ETF TA-Growth0.01871.727556941.2597
2024-01-311290 VT Micro Cap K0.01640.014663200
2024-02-29Dimensional US Targeted Value ETF0.01620.0002653100
2023-12-31I.B.I Up to 3 Years 90/10 IL0.01490.1392600000
2023-09-30Blackstone Alternative Multi-Strategy I0.01260.00035100-1700-25
2023-12-31I.B.I US Equities0.01240.0577500000
2024-02-29Avantis US Equity ETF0.01030.0002415200
2023-12-31Harel HTF TA All-Share IL0.00990.42674004641.6244
2024-02-29Dimensional US Equity ETF0.00850.0001343100
2023-12-31NT Quality SCC US Fund - L0.00650.0024260300
2023-12-31NT Quality Small Cap Core0.00650.0025260300
Total 0.8075.3464325529+1583+0.5%

3.3. Insider Transactions

Insiders are holding 11.23% of the shares of Oramed Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-03-16Nadav KidronBUY260002.04
2023-03-14Nadav KidronBUY1000002.01
2023-03-13Yadin RozovBUY200001.96
2023-01-03Michael RabinowitzSELL1332512.55
2022-03-21Kevin RakinSELL100009.41
2021-09-16Kevin RakinSELL2110020.99
2021-08-09Nadav KidronSELL22000020.11

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Oramed Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.3620.072+400%-0.121+133%0.165+119%0.096+277%
Book Value Per Share--4.0203.782+6%3.823+5%2.262+78%1.424+182%
Current Ratio--3.05543.534-93%23.901-87%19.043-84%17.540-83%
Debt To Asset Ratio--0.2610.180+45%0.062+321%0.223+17%0.238+10%
Debt To Equity Ratio--0.3520.253+39%0.066+433%0.343+3%0.396-11%
Dividend Per Share----0%-0%-0%-0%
Eps--0.3290.048+590%-0.226+169%-0.099+130%-0.072+122%
Free Cash Flow Per Share---0.035-0.081+132%-0.175+400%-0.113+222%-0.074+110%
Free Cash Flow To Equity Per Share---0.6520.372-275%-0.109-83%0.222-393%0.146-547%
Gross Profit Margin--1.0001.104-9%1.039-4%1.032-3%1.016-2%
Intrinsic Value_10Y_max--4.438--------
Intrinsic Value_10Y_min---4.165--------
Intrinsic Value_1Y_max---0.188--------
Intrinsic Value_1Y_min---0.508--------
Intrinsic Value_3Y_max---0.084--------
Intrinsic Value_3Y_min---1.458--------
Intrinsic Value_5Y_max--0.603--------
Intrinsic Value_5Y_min---2.323--------
Market Cap89142240.000-1%89952624.000117910872.000-24%323545812.000-72%267041787.600-66%286042253.460-69%
Net Profit Margin----3.5790%-13.6150%-7.2620%-5.9380%
Operating Margin----4.9820%-15.0360%-7.9370%-6.2470%
Operating Ratio---5.482-100%16.036-100%8.901-100%8.624-100%
Pb Ratio0.547-1%0.5520.775-29%2.082-73%4.470-88%8.928-94%
Pe Ratio1.671-1%1.686-15.179+1000%-9.191+645%-11.338+772%-18.521+1198%
Price Per Share2.200-1%2.2202.910-24%7.985-72%6.591-66%7.059-69%
Price To Free Cash Flow Ratio-15.683+1%-15.826-19.888+26%-15.956+1%-17.212+9%-26.216+66%
Price To Total Gains Ratio6.079-1%6.135-125.137+2140%727.864-99%110.400-94%-8.150+233%
Quick Ratio--2.87582.410-97%35.328-92%32.228-91%30.814-91%
Return On Assets--0.060-0.003+106%-0.056+192%-0.060+199%-0.067+211%
Return On Equity--0.081-0.001+101%-0.059+173%-0.085+204%-0.097+219%
Total Gains Per Share--0.3620.072+400%-0.121+133%0.165+119%0.096+277%
Usd Book Value--162893000.000153233500.000+6%154890750.000+5%91654650.000+78%57699970.800+182%
Usd Book Value Change Per Share--0.3620.072+400%-0.121+133%0.165+119%0.096+277%
Usd Book Value Per Share--4.0203.782+6%3.823+5%2.262+78%1.424+182%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.3290.048+590%-0.226+169%-0.099+130%-0.072+122%
Usd Free Cash Flow---1421000.000-3292750.000+132%-7103500.000+400%-4569100.000+222%-2991184.925+110%
Usd Free Cash Flow Per Share---0.035-0.081+132%-0.175+400%-0.113+222%-0.074+110%
Usd Free Cash Flow To Equity Per Share---0.6520.372-275%-0.109-83%0.222-393%0.146-547%
Usd Market Cap89142240.000-1%89952624.000117910872.000-24%323545812.000-72%267041787.600-66%286042253.460-69%
Usd Price Per Share2.200-1%2.2202.910-24%7.985-72%6.591-66%7.059-69%
Usd Profit--13336000.00094250.000+14050%-9188500.000+169%-4403450.000+133%-3458642.000+126%
Usd Revenue---338750.000-100%675750.000-100%608700.000-100%489625.275-100%
Usd Total Gains Per Share--0.3620.072+400%-0.121+133%0.165+119%0.096+277%
 EOD+3 -5MRQTTM+19 -13YOY+18 -145Y+18 -1410Y+20 -12

4.2. Fundamental Score

Let's check the fundamental score of Oramed Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-151.671
Price to Book Ratio (EOD)Between0-10.547
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.875
Current Ratio (MRQ)Greater than13.055
Debt to Asset Ratio (MRQ)Less than10.261
Debt to Equity Ratio (MRQ)Less than10.352
Return on Equity (MRQ)Greater than0.150.081
Return on Assets (MRQ)Greater than0.050.060
Total7/10 (70.0%)

4.3. Technical Score

Let's check the technical score of Oramed Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.425
Ma 20Greater thanMa 502.655
Ma 50Greater thanMa 1002.909
Ma 100Greater thanMa 2002.623
OpenGreater thanClose2.340
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-11-302023-02-282023-05-312023-08-312023-11-30
Income before Tax  -8,7360-8,7367,423-1,313-1,971-3,28416,58013,296
Net Income  -8,5430-8,5437,349-1,194-2,028-3,22216,55813,336
Net Income from Continuing Operations  -8,7365,125-3,6112,298-1,313-1,971-3,28416,58013,296



Latest Balance Sheet

Balance Sheet of 2023-11-30. Currency in USD. All numbers in thousands.

Summary
Total Assets220,551
Total Liabilities57,658
Total Stockholder Equity163,821
 As reported
Total Liabilities 57,658
Total Stockholder Equity+ 163,821
Total Assets = 220,551

Assets

Total Assets220,551
Total Current Assets162,584
Long-term Assets57,967
Total Current Assets
Cash And Cash Equivalents 9,055
Short-term Investments 152,992
Other Current Assets 537
Total Current Assets  (as reported)162,584
Total Current Assets  (calculated)162,584
+/-0
Long-term Assets
Property Plant Equipment 1,567
Long Term Investments 54,926
Long-term Assets  (as reported)57,967
Long-term Assets  (calculated)56,493
+/- 1,474

Liabilities & Shareholders' Equity

Total Current Liabilities53,214
Long-term Liabilities4,444
Total Stockholder Equity163,821
Total Current Liabilities
Short Long Term Debt 51,013
Accounts payable 551
Total Current Liabilities  (as reported)53,214
Total Current Liabilities  (calculated)51,564
+/- 1,650
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt609
Long-term Liabilities Other 63
Long-term Liabilities  (as reported)4,444
Long-term Liabilities  (calculated)672
+/- 3,772
Total Stockholder Equity
Total Stockholder Equity (as reported)163,821
Total Stockholder Equity (calculated)0
+/- 163,821
Other
Capital Stock485
Common Stock Shares Outstanding 40,339
Net Debt 41,958
Net Invested Capital 214,834
Net Working Capital 109,370
Property Plant and Equipment Gross 1,567



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-11-302023-08-312023-05-312023-02-282022-11-302022-08-312022-05-312022-02-282021-11-302021-08-312021-05-312021-02-282020-11-302020-08-312020-05-312020-02-292019-11-302019-08-312019-05-312019-02-282018-11-302018-08-312018-05-312018-02-282017-11-302017-08-312017-05-312017-02-282016-11-302016-08-312016-05-312016-02-292015-11-302015-08-312015-05-312015-02-282014-11-302014-08-312014-05-312014-02-282013-11-302013-08-312013-05-312013-02-282012-11-302012-08-312012-05-312012-02-292011-11-302011-08-312011-05-312011-02-282010-11-302010-08-312010-05-312010-02-282009-11-302009-08-312009-05-312009-02-282008-11-302008-08-312008-05-312008-02-292007-11-302007-08-312007-05-312007-02-282006-11-302006-08-312006-05-312006-02-282005-11-302005-08-312005-05-312005-02-282004-11-302004-02-292003-11-302003-08-312003-05-31
> Total Assets 
4,286
1,014
1,014
240
0
0
0
-40
0
0
191
176
176
133
963
1,937
1,937
1,319
2,825
5,507
4,321
3,713
3,347
3,262
2,960
2,528
2,116
1,451
1,359
3,892
4,964
4,326
3,903
3,143
2,474
5,295
5,295
5,957
4,846
8,660
8,006
23,710
22,498
21,802
24,560
22,980
22,129
26,354
23,883
38,372
36,305
42,830
44,928
41,836
39,792
38,712
41,544
38,254
34,659
47,397
43,593
41,810
37,432
34,663
31,142
29,881
46,155
44,633
40,971
61,657
80,492
127,999
182,450
172,224
162,291
164,437
161,642
161,642
156,314
230,893
220,551
220,551230,893156,314161,642161,642164,437162,291172,224182,450127,99980,49261,65740,97144,63346,15529,88131,14234,66337,43241,81043,59347,39734,65938,25441,54438,71239,79241,83644,92842,83036,30538,37223,88326,35422,12922,98024,56021,80222,49823,7108,0068,6604,8465,9575,2955,2952,4743,1433,9034,3264,9643,8921,3591,4512,1162,5282,9603,2623,3473,7134,3215,5072,8251,3191,9371,93796313317617619100-400002401,0141,0144,286
   > Total Current Assets 
4,286
1,014
1,014
240
0
0
0
-40
0
0
191
176
176
133
963
1,930
1,930
1,229
2,721
5,398
4,217
3,614
3,253
3,174
2,881
2,456
2,053
1,397
1,310
3,835
4,931
4,284
3,865
3,108
2,458
5,276
5,276
5,939
4,824
8,644
7,986
23,687
15,970
21,778
24,533
18,295
17,303
17,372
15,188
26,035
25,142
31,230
30,495
29,780
26,348
20,297
19,135
21,127
23,582
31,037
29,651
29,601
26,588
33,324
30,742
29,489
41,303
40,511
36,024
57,472
72,233
95,337
152,332
143,562
134,870
160,172
157,109
157,109
150,970
175,705
162,584
162,584175,705150,970157,109157,109160,172134,870143,562152,33295,33772,23357,47236,02440,51141,30329,48930,74233,32426,58829,60129,65131,03723,58221,12719,13520,29726,34829,78030,49531,23025,14226,03515,18817,37217,30318,29524,53321,77815,97023,6877,9868,6444,8245,9395,2765,2762,4583,1083,8654,2844,9313,8351,3101,3972,0532,4562,8813,1743,2533,6144,2175,3982,7211,2291,9301,93096313317617619100-400002401,0141,0144,286
       Cash And Cash Equivalents 
4,286
1,014
1,014
240
0
0
0
-40
0
0
191
176
176
133
963
1,918
1,918
1,145
2,659
2,267
2,191
3,438
3,218
1,717
1,146
725
1,135
1,200
1,101
1,932
1,920
1,513
1,496
1,824
1,300
4,431
4,431
2,040
1,105
2,272
1,371
3,253
2,475
1,762
6,656
1,102
3,847
3,213
1,949
3,230
3,302
3,907
2,290
1,452
1,733
3,969
1,258
3,295
3,673
4,996
3,861
3,429
3,946
3,329
3,171
5,934
9,313
19,296
14,931
33,805
57,414
77,245
31,880
27,967
29,892
33,196
40,464
40,464
6,767
5,468
9,055
9,0555,4686,76740,46440,46433,19629,89227,96731,88077,24557,41433,80514,93119,2969,3135,9343,1713,3293,9463,4293,8614,9963,6733,2951,2583,9691,7331,4522,2903,9073,3023,2301,9493,2133,8471,1026,6561,7622,4753,2531,3712,2721,1052,0404,4314,4311,3001,8241,4961,5131,9201,9321,1011,2001,1357251,1461,7173,2183,4382,1912,2672,6591,1451,9181,91896313317617619100-400002401,0141,0144,286
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,728
1,728
0
0
1,000
1,400
1,400
500
100
100
1,777
2,416
385
2,185
1,180
500
200
200
3,305
3,127
6,203
6,422
20,098
13,069
19,528
17,714
17,046
13,307
14,016
13,111
22,372
21,403
27,109
27,759
28,161
24,472
16,153
17,714
17,608
19,700
25,467
25,063
25,222
22,248
28,953
26,962
22,992
31,520
20,604
19,417
22,984
12,227
16,895
118,655
113,643
104,020
126,353
115,256
115,256
143,434
169,571
152,992
152,992169,571143,434115,256115,256126,353104,020113,643118,65516,89512,22722,98419,41720,60431,52022,99226,96228,95322,24825,22225,06325,46719,70017,60817,71416,15324,47228,16127,75927,10921,40322,37213,11114,01613,30717,04617,71419,52813,06920,0986,4226,2033,1273,3052002005001,1802,1853852,4161,7771001005001,4001,4001,000001,7282,7280000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
437
295
213
302
72
168
87
562
567
150
75
264
88
88
543
513
63
5
75
268
408
27
2
33
33
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
805
0
0
0
290
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000290000805000000000000000333322740826875563513543888826475150567562871687230221329543700000000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12
84
62
403
298
176
35
20
40
118
117
8
1
6
8
1,801
35
29
394
457
539
36
62
90
173
246
98
64
120
129
100
127
112
417
421
198
430
151
127
159
163
224
209
574
727
950
394
1,042
609
563
470
611
1,676
683
2,592
1,197
1,797
1,952
958
623
1,389
1,389
769
666
537
5376667691,3891,3896239581,9521,7971,1972,5926831,6766114705636091,042394950727574209224163159127151430198421417112127100129120649824617390623653945739429351,80186181171184020351762984036284120000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
90
104
109
104
100
94
88
80
71
62
54
49
57
33
42
37
34
16
18
18
18
23
16
19
23
6,529
24
27
4,685
4,826
8,982
8,695
12,337
11,163
11,600
14,433
12,056
13,444
18,415
22,409
17,127
11,077
16,360
13,942
12,209
10,844
1,339
400
392
4,852
4,122
4,947
4,185
8,259
32,662
30,118
28,662
27,421
4,265
4,533
4,533
5,344
55,188
57,967
57,96755,1885,3444,5334,5334,26527,42128,66230,11832,6628,2594,1854,9474,1224,8523924001,33910,84412,20913,94216,36011,07717,12722,40918,41513,44412,05614,43311,60011,16312,3378,6958,9824,8264,68527246,52923191623181818163437423357495462718088941001041091049070000000000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
83
93
98
92
86
80
75
67
60
52
43
36
30
22
17
11
8
2
5
5
2
6
6
9
12
14
14
15
13
12
11
12
11
17
16
15
16
17
18
17
18
17
17
23
21
27
24
133
124
111
174
1,049
1,023
949
932
889
1,532
1,505
1,540
1,809
1,809
1,787
1,691
1,567
1,5671,6911,7871,8091,8091,5401,5051,5328899329491,0231,0491741111241332427212317171817181716151617111211121315141412966255281117223036435260677580869298938322000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11
9
9
9
9
9
9
5
5
5
6,508
3
5
4,665
4,806
8,962
8,674
12,317
11,136
11,573
14,407
1,023
13,414
18,383
22,378
17,094
11,045
16,327
13,903
12,171
10,800
1,295
251
251
4,724
3,930
3,880
3,142
7,288
31,708
29,205
1,955
684
2,700
2,700
2,700
3,524
53,465
54,926
54,92653,4653,5242,7002,7002,7006841,95529,20531,7087,2883,1423,8803,9304,7242512511,29510,80012,17113,90316,32711,04517,09422,37818,38313,4141,02314,40711,57311,13612,3178,6748,9624,8064,665536,5085559999991100000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
27
11
25
26
27
14
14
14
16
16
10
11
11
6,514
10
12
4,672
4,814
8,971
8,683
12,326
11,146
11,584
14,418
12,040
13,427
18,397
22,392
17,109
8,767
17
16
17
17
20
17
18
19
20
20
22
22
25,040
25,098
25,175
25,232
25
31
0
33
0
0
00330312525,23225,17525,09825,0402222202019181720171716178,76717,10922,39218,39713,42712,04014,41811,58411,14612,3268,6838,9714,8144,67212106,51411111016161414142726251127130000000000000000000000000000
> Total Liabilities 
8,892
0
18,232
21,856
0
0
30
50
50
51
370
609
609
716
1,739
1,424
1,424
939
2,363
914
660
544
475
516
559
429
433
621
544
728
522
602
585
744
503
1,517
1,517
709
687
529
700
382
527
1,009
863
641
802
1,526
1,342
5,667
5,322
16,640
20,942
20,514
19,982
19,474
18,803
17,774
18,002
16,285
14,735
16,462
15,875
15,270
13,982
13,791
12,043
11,754
12,759
12,215
11,297
11,482
11,759
10,001
9,254
11,290
10,486
10,486
5,659
82,663
57,658
57,65882,6635,65910,48610,48611,2909,25410,00111,75911,48211,29712,21512,75911,75412,04313,79113,98215,27015,87516,46214,73516,28518,00217,77418,80319,47419,98220,51420,94216,6405,3225,6671,3421,5268026418631,0095273827005296877091,5171,5175037445856025227285446214334295595164755446609142,3639391,4241,4241,739716609609370515050300021,85618,23208,892
   > Total Current Liabilities 
4,446
9,116
9,116
10,928
0
0
30
50
50
51
370
609
609
716
1,739
1,424
1,424
939
2,363
914
660
544
475
369
412
282
286
459
382
566
360
441
424
582
356
644
644
469
446
498
669
350
495
973
827
605
765
1,489
1,304
1,519
1,338
3,621
4,734
4,933
5,036
5,165
5,124
4,718
5,637
4,553
4,164
5,104
5,216
5,308
4,641
5,155
4,135
4,536
5,742
5,932
5,750
6,679
7,660
6,324
6,418
6,525
5,746
5,746
1,067
78,175
53,214
53,21478,1751,0675,7465,7466,5256,4186,3247,6606,6795,7505,9325,7424,5364,1355,1554,6415,3085,2165,1044,1644,5535,6374,7185,1245,1655,0364,9334,7343,6211,3381,5191,3041,4897656058279734953506694984464696446443565824244413605663824592862824123694755446609142,3639391,4241,4241,739716609609370515050300010,9289,1169,1164,446
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
125
275
275
275
275
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
46
32
32
44
138
139
129
130
130
237
233
228
0
247
236
75,614
0
075,61423624702282332371301301291391384432324600000000000000000000000000000000000000000000002752752752751250000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
75,363
51,013
51,01375,3630000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
4,446
0
9,116
10,928
0
0
0
40
4
4
21
0
54
38
11
0
341
158
318
914
660
544
47
47
47
282
286
47
47
47
47
47
47
47
47
644
47
469
446
440
669
350
495
926
795
570
731
953
768
829
646
1,411
2,237
2,424
2,526
571
1,582
2,156
3,143
1,135
2,982
2,346
2,474
1,337
1,796
2,377
1,350
594
2,808
3,003
2,860
2,606
4,761
3,310
3,481
4,205
2,176
2,175
828
2,561
551
5512,5618282,1752,1764,2053,4813,3104,7612,6062,8603,0032,8085941,3502,3771,7961,3372,4742,3462,9821,1353,1432,1561,5825712,5262,4242,2371,4116468297689537315707959264953506694404464694764447474747474747472862824747475446609143181583410113854021444000010,9289,11604,446
       Other Current Liabilities 
0
0
0
0
0
0
30
10
46
47
349
0
555
553
1,453
0
808
506
2,045
0
0
0
428
321
364
0
0
411
335
519
313
394
377
535
309
63
597
47
47
59
47
47
47
47
32
35
34
36
36
41
42
48
47
60
61
2,145
1,093
113
45
969
51
55
39
1,268
96
43
50
1,195
93
87
58
1,240
66
74
1
70
1,351
1,984
-3,997
-4,000
0
0-4,000-3,9971,9841,35170174661,2405887931,1955043961,268395551969451131,0932,14561604748424136363435324747474759474759763309535377394313519335411003643214280002,04550680801,453553555034947461030000000
   > Long-term Liabilities 
4,446
0
9,116
10,928
0
0
0
40
4
4
21
0
54
163
286
0
616
433
318
914
660
544
47
147
147
147
147
162
162
162
162
161
161
162
147
872
872
240
241
31
32
32
32
36
36
36
37
37
38
4,148
3,984
13,019
16,208
15,581
14,946
14,309
13,679
13,056
12,365
11,732
10,571
11,358
10,659
9,962
9,341
8,636
7,908
7,218
7,017
6,283
5,547
4,803
4,099
3,677
2,836
4,765
4,740
4,740
4,592
4,488
4,444
4,4444,4884,5924,7404,7404,7652,8363,6774,0994,8035,5476,2837,0177,2187,9088,6369,3419,96210,65911,35810,57111,73212,36513,05613,67914,30914,94615,58116,20813,0193,9844,1483837373636363232323124124087287214716216116116216216216214714714714747544660914318433616028616354021444000010,9289,11604,446
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
162
162
162
161
161
162
147
873
240
240
241
31
32
32
32
36
36
36
37
37
38
4,148
3,984
13,019
16,208
15,581
14,946
14,309
13,679
13,056
12,365
11,732
10,571
11,358
10,659
9,962
9,281
8,569
7,851
7,187
6,515
5,814
5,116
4,400
3,725
2,806
2,092
4,093
4,093
0
4,104
0
0
004,10404,0934,0932,0922,8063,7254,4005,1165,8146,5157,1877,8518,5699,2819,96210,65911,35810,57111,73212,36513,05613,67914,30914,94615,58116,20813,0193,9844,148383737363636323232312412402408731471621611611621621620000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,109
3,945
12,604
15,682
15,072
14,455
13,837
13,226
12,622
12,005
11,388
0
0
0
0
8,983
8,309
7,629
6,947
6,273
5,606
4,925
0
3,570
0
0
0
0
0
0
0
0
000000003,57004,9255,6066,2736,9477,6298,3098,983000011,38812,00512,62213,22613,83714,45515,07215,68212,6043,9454,1090000000000000000000000000000000000000000000000000
> Total Stockholder Equity
-4,606
0
-17,218
-21,616
0
0
-330
-50
-50
-51
-178
0
-433
-583
-776
0
513
380
462
4,593
3,661
3,170
2,872
2,746
2,402
2,098
1,682
830
814
3,165
4,442
3,724
3,317
2,398
1,972
3,778
3,778
5,248
4,159
8,131
7,305
23,328
21,971
20,793
23,697
22,339
21,327
24,828
22,541
32,705
30,983
26,190
23,986
21,322
19,810
19,238
22,741
20,480
16,657
31,112
28,858
25,348
21,557
19,393
17,160
16,090
34,112
32,879
28,212
49,442
68,118
115,773
170,155
162,349
153,697
153,808
151,812
151,812
151,546
149,132
163,821
163,821149,132151,546151,812151,812153,808153,697162,349170,155115,77368,11849,44228,21232,87934,11216,09017,16019,39321,55725,34828,85831,11216,65720,48022,74119,23819,81021,32223,98626,19030,98332,70522,54124,82821,32722,33923,69720,79321,97123,3287,3058,1314,1595,2483,7783,7781,9722,3983,3173,7244,4423,1658148301,6822,0982,4022,7462,8723,1703,6614,5934623805130-776-583-4330-178-51-50-50-33000-21,616-17,2180-4,606
   Common Stock
0
0
0
0
20
20
20
20
18
41
41
0
41
42
42
0
45
46
48
56
56
56
56
56
57
57
57
58
59
68
70
70
70
70
70
80
80
87
87
95
95
117
119
121
129
129
129
138
138
157
157
157
158
159
159
163
170
171
172
207
207
207
207
208
209
214
279
284
286
339
366
424
458
463
463
470
476
476
484
484
0
04844844764764704634634584243663392862842792142092082072072072071721711701631591591581571571571381381291291291211191179595878780807070707070685958575757565656565648464504242410414118202020200000
   Retained Earnings Total Equity00000000-122,742-114,852-107,999-102,792-98,184-92,614-89,618-87,334-83,6460-78,823-74,751-71,050-69,223-66,297-61,943-59,027-56,496-53,800-51,835-48,652-46,016-41,256-39,260-37,442-35,052-32,936-31,353-29,716-27,820-26,191-24,363-23,248-22,124-21,333-20,076-18,851-17,870-16,562-16,011-15,02600000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
-23
-23
0
0
-21
0
0
0
0
0
-15
-15
0
0
-46
-46
0
0
-78
-78
0
38
-106
-4
0
16
-121
-121
245
132
303
334
847
468
452
93
100
163
558
152
230
314
106
43
211
497
401
727
313
198
702
1,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000001,0007021983137274014972114310631423015255816310093452468847334303132245-121-121160-4-106380-78-7800-46-4600-15-1500000-2100-23-23000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,277
18,339
18,447
21,568
24,778
24,993
25,273
29,856
30,124
46,726
47,574
48,040
53,191
53,463
53,971
59,184
59,693
71,578
71,768
71,943
72,437
72,787
72,954
75,170
80,871
81,939
82,584
99,426
99,701
99,892
100,173
100,288
100,597
103,210
123,451
125,209
126,110
151,895
175,751
230,201
292,439
0
0
0
0
0
0
0
0
00000000292,439230,201175,751151,895126,110125,209123,451103,210100,597100,288100,17399,89299,70199,42682,58481,93980,87175,17072,95472,78772,43771,94371,76871,57859,69359,18453,97153,46353,19148,04047,57446,72630,12429,85625,27324,99324,77821,56818,44718,33918,27700000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
330
760
766
766
766
0
769
1,048
1,129
0
4,947
5,502
6,403
11,800
12,056
12,208
12,423
12,744
12,966
13,055
13,445
13,837
14,344
17,329
18,146
18,307
18,277
18,339
18,447
0
21,711
24,993
25,273
29,856
30,124
46,726
47,574
48,040
53,191
53,463
53,971
59,184
59,693
71,578
71,768
71,943
72,437
72,787
72,954
75,170
80,871
81,939
82,584
99,426
99,701
99,892
100,173
100,288
100,597
103,210
123,451
125,209
126,110
151,895
175,751
230,201
292,439
298,831
300,712
307,876
0
314,417
318,732
319,540
0
0319,540318,732314,4170307,876300,712298,831292,439230,201175,751151,895126,110125,209123,451103,210100,597100,288100,17399,89299,70199,42682,58481,93980,87175,17072,95472,78772,43771,94371,76871,57859,69359,18453,97153,46353,19148,04047,57446,72630,12429,85625,27324,99321,711018,44718,33918,27718,30718,14617,32914,34413,83713,44513,05512,96612,74412,42312,20812,05611,8006,4035,5024,94701,1291,0487690766766766760330000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-08-31)

Gross Profit (+$)
totalRevenue2,703
Cost of Revenue-0
Gross Profit2,7032,703
 
Operating Income (+$)
Gross Profit2,703
Operating Expense-43,301
Operating Income-40,598-40,598
 
Operating Expense (+$)
Research Development27,639
Selling General Administrative13,811
Selling And Marketing Expenses1,851
Operating Expense43,30143,301
 
Net Interest Income (+$)
Interest Income4,626
Interest Expense-2,934
Other Finance Cost-2,925
Net Interest Income4,617
 
Pretax Income (+$)
Operating Income-40,598
Net Interest Income4,617
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-37,664-43,532
EBIT - interestExpense = -43,532
-37,664
-34,830
Interest Expense2,934
Earnings Before Interest and Taxes (EBIT)-40,598-34,730
Earnings Before Interest and Taxes (EBITDA)-36,976
 
After tax Income (+$)
Income Before Tax-37,664
Tax Provision-0
Net Income From Continuing Ops-30,667-37,664
Net Income-37,764
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses43,301
Total Other Income/Expenses Net2,934-4,617
 

Technical Analysis of Oramed
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Oramed. The general trend of Oramed is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Oramed's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Oramed Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.14 < 3.61 < 3.62.

The bearish price targets are: 2.1 > 2.1 > 2.1.

Tweet this
Oramed Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Oramed Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Oramed Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Oramed Pharmaceuticals Inc. The current macd is -0.14997365.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Oramed price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Oramed. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Oramed price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Oramed Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartOramed Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Oramed Pharmaceuticals Inc. The current adx is 17.09.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Oramed shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Oramed Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Oramed Pharmaceuticals Inc. The current sar is 2.80386729.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Oramed Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Oramed Pharmaceuticals Inc. The current rsi is 29.42. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
Oramed Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartOramed Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Oramed Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Oramed price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Oramed Pharmaceuticals Inc Daily Stochastic Oscillator ChartOramed Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Oramed Pharmaceuticals Inc. The current cci is -193.91006098.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Oramed Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartOramed Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Oramed Pharmaceuticals Inc. The current cmo is -57.2277581.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Oramed Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartOramed Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Oramed Pharmaceuticals Inc. The current willr is -92.59259259.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Oramed Pharmaceuticals Inc Daily Williams %R ChartOramed Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Oramed Pharmaceuticals Inc. The current atr is 0.16763749.

Oramed Pharmaceuticals Inc Daily Average True Range (ATR) ChartOramed Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Oramed Pharmaceuticals Inc. The current obv is -14,069,383.

Oramed Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartOramed Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Oramed Pharmaceuticals Inc. The current mfi is 5.11725719.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Oramed Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartOramed Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Oramed Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-26BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-29MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Oramed Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Oramed Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.425
Ma 20Greater thanMa 502.655
Ma 50Greater thanMa 1002.909
Ma 100Greater thanMa 2002.623
OpenGreater thanClose2.340
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Oramed with someone you think should read this too:
  • Are you bullish or bearish on Oramed? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Oramed? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Oramed Pharmaceuticals Inc

I send you an email if I find something interesting about Oramed Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Oramed Pharmaceuticals Inc.

Receive notifications about Oramed Pharmaceuticals Inc in your mailbox!